Abbott Laboratories (NYSE:ABT) reached 40.45% versus a 1-year low price of $60.32. The stock was last seen -0.34% lower, reaching at $84.71 on 6/24/2019. At a recent session, the prices were hovering between $84.64 and $85.33. This company shares are -1.95% up from its target price of $83.06 and the current market capitalization stands at $149.34B. The recent change has given its price a 8.41% lead over SMA 50 and -0.76% deficit over its 52-week high. The stock witnessed 12.01% gains, 8.28% gains and 23.88% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ABT’s volatility during a week at 1.38% and during a month it has been found around 1.43%.

What Does Abbott Laboratories (ABT) Do?

The company describes itself in regulatory filings as, “Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.” [Text can be found here: https://www.marketwatch.com/investing/stock/ABT/profile under company description.]

Abbott Laboratories (ABT) Top Holders

Institutional investors currently hold around $111.81 billion or 76% in ABT stock. Look at its top three institutional owners: Vanguard Group Inc owns $12.42 billion in Abbott Laboratories, which represents roughly 8.31% of the company’s market cap and approximately 11.1% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 124,326,366 shares of the stock are valued at $10.57 billion. The third largest holder is Capital Research Global Investors, which currently holds $9.82 billion worth of this stock and that ownership represents nearly 6.58% of its market capitalization.

Abbott Laboratories 13F Filings

At the end of March reporting period, 821 institutional holders increased their position in Abbott Laboratories (NYSE:ABT) by some 52,498,588 shares, 965 decreased positions by 61,921,374 and 304 held positions by 1,201,000,000. That puts total institutional holdings at 1,315,000,000 shares, according to SEC filings. The stock grabbed 134 new institutional investments totaling 2,732,924 shares while 84 institutional investors sold out their entire positions totaling 7,009,161 shares.

Abbott Laboratories (NYSE:ABT) Insider Trades

Multiple company employees have indulged in significant insider trading. Abbott Laboratories disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Executive Vice President Wainer Andrea F has sold 1,188 shares of Abbott Laboratories (ABT) in the trading session dated Jun. 21, 2019. These shares are worth $101,134 and were traded at $85.13 each. The SEC filing shows that ALLEN HUBERT L performed a sale of 165,000 shares. The Executive Vice President disposed these shares by way of transaction on Jun. 20, 2019. The company’s shares were given away at $85 per share worth to an income of some $14,025,000 to the account of ALLEN HUBERT L.

Executive Vice President, CAPEK JOHN M, sold 46,900 common shares of Abbott Laboratories (ABT) in the open market. In a transaction dated Jun. 20, 2019, the shares were put up for sale at an average price of $85, raking in a sum of $3,986,500. After this sale, 308,535 common shares of ABT are directly owned by the insider, with total stake valued at $26,136,000.

In the transaction dated Jun. 13, 2019, a great number of shares sold came courtesy the Executive Vice President; Salvadori Daniel Gesua Sive disposed a total of 10,600 shares at an average price of $82, amounting to approximately $869,200. The insider now directly owns 96,148 shares worth $8,144,697.

Abbott Laboratories (ABT) Analyst Guide

Several analysts have released their opinion on Abbott Laboratories (NYSE:ABT), with 9 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 8 buy, 0 sell and 1 strong sell ratings, collectively assigning a 1.8 average brokerage recommendation [T1].